Effect of different statins on the antifungal activity of polyene antimycotics

Acta Biologica Szegediensis

Volumn 54, Issue 1, 2010, Pages 33-36

  Nyilasi, Ildikó ^a   Kocsubé, Sándor ^a   Galgóczy, László ^a   Papp, Tamás ^a   Pesti, Miklós ^b   Vágvölgyi, Csaba ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Amphotericin B; Drug interaction; Microscopic fungi; Nystatin; Statins

Indexed keywords

AMPHOTERICIN B; ATORVASTATIN; ATORVOX; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NYSTATIN; POLYENE ANTIBIOTIC AGENT; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; VASILIP;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; BROTH DILUTION; CANDIDA ALBICANS; CANDIDA GLABRATA; DRUG EFFECT; DRUG POTENTIATION; FUNGUS GROWTH; MINIMUM INHIBITORY CONCENTRATION; PAECILOMYCES; RHIZOPUS ORYZAE;

ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CANDIDA GLABRATA; FUNGI; PAECILOMYCES VARIOTII; RHIZOPUS ORYZAE;

EID: 77957677552     PISSN: 1588385X     EISSN: 15884082     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Afeltra J, Verweij PE (2003) Antifungal activity of nonantifungal drags. Eur J Clin Microbiol Infect Dis 22:397-407.
2. Baddley JW, Pappas PG (2005) Antifungal combination therapy: clinical potential. Drags 65:1461-80.
3. Chamilos G, Lewis RE, Kontoyiannis DP (2006) Lovastatin has significant activity against Zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother 50:96-103.
4. Chin NX, Weitzman I, Della-Latta P (1997) In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with fluconazole and itraconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother 41:850-852.
5. Galgóczy L, Ördögh L, Virágh M, Papp T, Vágvölgyi Cs (2009a) In vitro susceptibility of clinically important Zygomycetes to combinations of amphotericin B and suramin. J Mycol Med 19:241-247.
6. Galgóczy L, Nyilasi I, Papp T, Vágvölgyi Cs (2009b) Are statins applicable for prevention and treatment of zygomycosis? Clin Infect Dis 49:483-484.
7. Gallagher CG, Ashley ESD, Drew RH, Perfect JR (2003) Antifungal pharmacotherapy for invasive mould infections. Expt Opin Pharmacother 4:147-64.
8. Gisi U (1996) Synergistic interaction of fungicides in mixtures. Phytopathology 86:1273-1279.
9. Groll AH (2009) Update on invasive opportunistic mycoses: Clinical trials review, 2008-2009. Curr Infect Dis Rep 11:417-419.
10. Herman RJ (1999) Drug interactions and the statins. CMAJ 161:1281-1286.
11. Kontoyiannis DP (2007) Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. Clin Infect Dis 44:1089-1090.
12. Liao JK, Laufs U (2005) Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45:89-118.
13. Lorenz RT, Parks LW (1990) Effects of Lovastatin (Mevinolin) on sterol levels and on activity of azoles in Saccharomyces cerevisiae. Antimicrob Agents Chemother 34:1660-1665.
14. Lukács Gy, Papp T, Nyilasi I, Nagy E, Vágvölgyi Cs (2004) Differentiation of Rhizomucor species on the basis of their different sensitivities to lovastatin. J Clin Microbiol 42:5400-5402.
15. Macreadie IG, Johnson G, Schlosser T, Macreadie PI (2006) Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEMS Microbiol Lett 262:9-13.
16. Moen MD, Lyseng-Williamson KA, Scott LJ (2009) Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 69:361-392.
17. Nash JD, Burgess DS, Talbert RL (2002) Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans. J Med Microbiol 51:105-109.
18. Natesan SK, Chandrasekar PH, Alangaden GJ, Manavathu EK (2008) Fluvastatin potentiates the activity of caspofungin against Aspergillus fumigatus in vitro. Diagn Microbiol Infect Dis 60:369-73.
19. NCCLS (1997) Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. NCCLS document M27-A, Villanova, Pa, National Committee for Clinical Laboratory Standards, Wayne, PA.
20. NCCLS (2002) Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. NCCLS document M38-A, National Committee for Clinical Laboratory Standards, Wayne, PA.
21. Nosanchuk JD (2006) Current status and future of antifungal therapy for systemic mycoses. Recent Patents Anti-Infect. Drug Disc 1:75-84.
22. Nyilasi I, Kocsubé S, Pesti M, Lukács Gy, Papp T, Vágvölgyi Cs (2010) In vitro interactions between primycin and different statins in their effects against some clinically important fungi. J Med Microbiol 59:200-205.
23. Roze LV, Linz JE (1998) Lovastatin triggers an apoptosis-like cell death process in the fungus Mucor racemosus. Fungal Genet Biol 25:119-133.
24. Schachter M (2004) Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19:117-125.
25. Singh N (2001) Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 33:1692-1696.
26. Sun H-Y, Singh N (2009) Antimicrobial and immunomodulatory attributes of statins: relevance in solid-organ transplant recipients. Clin Infect Dis 48:745-755.
27. Tiphine M, Letscer-Bru V, Herbrecht R (1999). Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl Infect Dis 1:273-283.
28. Vazquez JA (2007) Combination antifungal therapy: the new frontier. Future Mcrobiol 2:115-139.